Skip to main content

Table 4 The prognostic potential of m6A regulatory genes and m6A associated genes

From: Roles of N6-methyladenosine (m6A) modifications in gynecologic cancers: mechanisms and therapeutic targeting

Prognostic genes/model

Univariate Cox Analyses

Multivariate Cox Analyses

Sample size

Refs.

HR (95 CI%)

P

HR (95 CI%)

P

OC

WTAP

NA

P = 0.021

1.191 (1.023–1.385)

P = 0.024

231

[84]

YTHDC2 and KIAA1429

3.143 (1.516–6.517)

P = 0.002

2.330 (1.116–4.865)

P = 0.024

379

[88]

IGF2BP1, VIRMA and ZC3H13

1.25 (1.10–1.43)

P < 0.001

1.24 (1.08–1.41)

P = 0.002

379

[86]

VIRMA, IGF2BP1, and HNRNPA2B1

1.62 (1.20–2.20)

P = 0.002

1.60 (1.18–2.17)

P = 0.003

374

[87]

WTAP, LGR6, ZC2HC1A, SLC4A8, AP2A1, NRAS, CUX1, HDAC1, CD79A, ACE2, FLG2, and LRFN1

1.664 (1.481–1.868)

P = 8.5E-18

1.699 (1.508–1.913)

P = 2.29E-18

373

[89]

CC

HNRNPC, KIAA1429, ZC3H13

2.268 (1.161–4.431)

P = 0.017

2.583 (1.289–5.174)

P = 0.007

306

[155]

ZC3H13, YTHDC1, and YTHDF1

NA

NA

4.592 (2.788–7.562)

P < 0.001

304

[156]

EC

FTO, RBM15, and YTHDF1

1.129 (1.065–1.197)

P < 0.001

1.090 (1.023–1.161)

P = 0.008

406

[205]

7 CpG sites (cg13823621, cg08881614, cg07867023, cg22247039, cg00624976 cg06778680 and, cg13204529)

NA

NA

4.3 (2.4–7.6)

P < 0.001

312

[206]

  1. NA not available